Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Fig. 1

Study flowchart. A total of 38 patients were enrolled into our study and randomly assigned to be treated with ambrisentan 5 or 10 mg/day or to receive placebo. After 6 months, 32 patients completed the study, 17 in the ambrisentan group, and 15 in the placebo group. Among the 6 dropout patients, 1 in the ambrisentan group and 2 in the placebo group withdrew their written informed consents. One in each group quit because of adverse events, one in the ambrisentan group for gingival bleeding, and one in the placebo group for angina pectoris. One patient in the placebo group was lost to follow-up

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us